Saturday - July 12, 2025

LOGIN  |  REGISTER
Assertio

LENSAR to Participate in Two Upcoming Investor Conferences

September 04, 2024 | Last Trade: US$13.03 0.08 -0.61

ORLANDO, Fla. / Sep 04, 2024 / Business Wire / LENSAR®, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced that management will participate in two upcoming investor conferences:

  • H.C. Wainwright 26th Annual Global Investment Conference
    On-demand presentation available Monday, September 9, 2024 at 7:00 a.m. Eastern Time.
  • Lake Street Capital Markets 8th Annual Best Ideas Growth Conference
    Management will conduct one-on-one meetings with institutional investors on September 12, 2024 in New York.

The on-demand H.C. Wainwright presentation will be available beginning at 7:00 a.m. Eastern Time on Monday, September 9, 2024 and can be accessed through the Investors section of the Company's website at https://ir.lensar.com.

About LENSAR

LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the cataract procedure. LENSAR has developed its ALLY® Adaptive Cataract Treatment System as a compact, highly ergonomic system utilizing an extremely fast dual-pulse laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reducing overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, which is designed to guide surgeons to achieve better outcomes.

Chimerix

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page